{
    "nctId": "NCT02413320",
    "briefTitle": "Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer",
    "officialTitle": "Randomized Open Label Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel or Carboplatin Plus Paclitaxel Followed by Doxorubicin Plus Cyclophosphamide in Stage I-III Triple-negative Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Triple-negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 101,
    "primaryOutcomeMeasure": "Number of Participants With Pathological Complete Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with newly diagnosed stage I (T\\>1cm), II or III triple negative breast cancer who have not had definitive breast surgery or received systemic chemotherapy\n* The invasive tumor must be hormone receptor-poor, defined as both estrogen receptor and progesterone receptor staining present in \u2264 10% of invasive cancer cells by Immunohistochemistry.\n* HER- 2 negativity will be based on the current ASCO-CAP guidelines for HER testing\n* No prior chemotherapy, endocrine therapy or radiation therapy with therapeutic intent for this cancer\n* Female subjects age 18 - 70 years\n* ECOG Performance Status of 0-1\n* Adequate organ and marrow function as defined below:\n\n  * Leukocytes \u2265 3,000/uL\n  * Absolute neutrophil count \u2265 1500/uL\n  * Platelets \u2265 100,000/uL\n  * Total bilirubin \u2264 1.5mg/dL\n  * AST(SGOT)/ALT(SPGT) \u2264 2 x institutional upper limit of normal\n  * Creatinine \u2264 1.5mg/dl and/or Creatinine Clearance \u2265 60mL/min\n  * Serum albumin \u2265 3.0 g/dL\n* Women of child-bearing potential must agree to use adequate contraception\n* Pretreatment lab values must be performed within 14 days of treatment initiation, and other baseline studies performed within 30 days prior to registration\n* Subjects should have LVEF \u2265 50% by echocardiogram or MUGA scan performed within 4 weeks prior to treatment initiation\n* Subjects should have breast and axillary imaging with breast MRI or breast and axillary ultrasound within 4 weeks prior to treatment initiation\n* Subjects with clinically/radiologically abnormal axillary lymph nodes should have pathological confirmation of disease with image guided biopsy/fine needle aspiration.\n* Subjects must be already enrolled in P.R.O.G.E.C.T observational registry\n* Staging to rule out metastatic disease is recommended for subjects with clinical stage III disease\n* Subjects with bilateral disease are eligible if they meet other eligibility criteria.\n* Neuropathy: No baseline neuropathy grade \\> 2\n\nExclusion Criteria:\n\n* Current or anticipated use of other investigational agents\n* Subject has received chemotherapy, radiotherapy or surgery for the treatment of breast cancer\n* Subject with metastatic disease\n* History of allergic reactions to compounds of similar chemical or biologic composition to carboplatin, docetaxel, doxorubicin, cyclophosphamide, paclitaxel, or other agents used in the study\n* Subjects with inflammatory breast cancer\n* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements\n* Subject is pregnant or nursing\n* Subjects with concomitant or previous malignancies within the last 5 years. Exceptions include: adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and ductal carcinoma in situ (DCIS).\n* Ejection Fraction \\<50% on ECHO or MUGA\n* Cardiac function: Subjects with congestive heart failure, myocardial infarction, unstable angina pectoris, an arterial thrombotic event, stroke or transient ischemia attack within the past 12 months, uncontrolled hypertension (Systolic BP\\>160 or Diastolic BP\\>90), uncontrolled or symptomatic arrhythmia, or grade \u2265 2 peripheral vascular disease",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}